For Practitioners
Flexible weekend and evening hours 212-288-3454

Leqembi Infusion for Alzheimer's and Memory Loss

Leqembi infusion therapy is FDA-approved to treat Alzheimer’s and may slow disease progression for patients in the early stages of the disease.

On this page:
  1. What is Leqembi?
  2. What is Alzheimer’s Disease?
  3. What is Cognitive Impairment?
  4. The Treatment Process
  5. Research
  6. FAQs
  7. About Keta Medical

What is Leqembi?

Leqembi is a groundbreaking medication that is clinically-proven to slow the progression of Alzheimer’s Disease at its earliest stages. It received FDA-approval in 2023 for the treatment of mild cognitive impairment and mild dementia. 

While Leqembi is not a cure for Alzheimer’s, it can help individuals maintain cognitive function for a longer period. In a large trial, Leqembi demonstrated a 27% slowing of progression vs placebo with increasing effect over time. Patients treated with Leqembi continued to show a different rate of progression through 36 months

In a Phase 3 clinical trial, Leqembi slowed cognitive decline by 27% compared to a placebo.

What is Alzheimer׳s Disease?

Alzheimer’s disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common cause of dementia and leads to a decline in cognitive function that interferes with daily life. Early symptoms including forgetfulness and confusion tend to worsen over time, impacting communication, judgment and the ability to perform routine tasks. Although there is currently no cure, early diagnosis and treatment can help manage symptoms and improve quality of life for those affected.

What is Cognitive Impairment?

Cognitive impairment refers to a decline in mental abilities such as memory, attention and reasoning. It can range from mild to severe and impacts daily functioning. Mild cognitive impairment (MCI) serves as an intermediate stage between normal aging and conditions like Alzheimer’s disease. Those with MCI may notice changes in cognitive function while often maintaining independence. Early recognition and intervention are essential for managing symptoms and enhancing quality of life.

The Process: Treating Cognitive Impairment with Leqembi

Eligibility
Assessment
If you have been prescribed Leqembi by your neurologist, we will reach out to them to obtain all the necessary information for you to start. If you have not been prescribed Leqembi, we will provide you with a checklist of testing that needs to be completed
Begin
Treatment
From the moment you enter our clinic, you’ll be greeted with a smile and a calm environment. After a quick exam, our staff ensures you’re completely comfortable and ready to begin.
During
Treatment​
Settle into a cozy reclining chair in a private room. You’ll receive an eye mask, noise-canceling headphones, and music options. Each treatment lasts 40-50 minutes, and our attentive medical team will be by your side.
Biweekly
Infusions

Leqembi is administered every other week. You can schedule an appointment at any one of our four locations.

"Everything about this medical office is first class. The staff is committed to helping you and your condition. I highly recommend this place!"
- David K.

FAQs

While Leqembi has shown promise in slowing the progression of Alzheimer’s disease, there are a number of tests required prior to the approval of treatment. Keta Medical Center will work with your neurologist to arrange for these tests prior to beginning treatment.

These tests include:

  • Medical Assessment: Conducted by your primary care provider or neurologist, this determines if you have mild cognitive impairment or mild Alzheimer’s Disease.
  • MRI: This scan of your brain will reveal if there are other causes of MCI.
  • Bloodwork: This will rule out other causes of cognitive impairments.
  • Genetic Testing: Genetic testing, completed using a sample of blood or saliva, assesses if you have a gene called APOE. The presence of this gene is associated with a greater susceptibility to the risks of treatment, which include micro-hemorrhages and edema in the brain.
  • A test for the presence of beta-amyloid in the brain: This can be a Positron Emission Tomography (PET) scan or a spinal fluid sample obtained using a lumbar puncture.
Yes. Assuming you complete all of the required tests, Leqembi treatments are covered by Medicare and other commercial insurance plans.
Patients must receive a Magnetic Resonance Imaging (MRI) scan of the brain before the 5th, 7th, and 14th infusions to ensure there is no brain bleeding and swelling.
Leqembi is an intravenous (IV) infusion. Each infusion takes about 1 hour with a short monitoring period afterwards. Infusions are given every 2 weeks.
Infusion related reactions including fever, flu-like symptoms, nausea, vomiting, dizziness, changes in heart rate or blood pressure, shortness of breath, serious allergic reactions, or ARIA (amyloid-related imaging abnormalities).

About Keta Medical Center

Keta Medical Center provides a compassionate and professional environment for individuals with cognitive impairment and Alzheimer’s disease. Founded by emergency room physicians Dr. Haviva Malina and Dr. Cheryl Malina, we are dedicated to offering cutting-edge and advanced treatment options that empower all of our patients and enhance their quality of life. Our commitment to excellence ensures that each patient receives personalized care, tailored to their unique needs.
We believe that effective care is a universal right.
Our inclusive and welcoming spaces are designed to make every patient feel comfortable, regardless of background or identity. We are dedicated to providing sensitive and affirming care to all, ensuring a supportive environment for everyone who walks through our doors.

Considering Leqembi?

If you or a loved one are facing early Alzheimer’s disease with mild cognitive impairment, Leqembi may be a suitable treatment option. At Keta Medical Center, we collaborate with your healthcare provider to assess if you are an appropriate candidate for this therapy.

The first step is a phone call.

;